• Home
  • A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma.

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma.

Author List
Fine H, Reid T, Caroen S, Oronsky B, Abrouk N, Butowski N
Publication
Frontiers in oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/410622948
Publication Year
2023
PubMed ID
37342189
Publication Title
Fine H, Reid T, Caroen S, Oronsky B, Abrouk N, Butowski N. A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma. Front Oncol. 2023; 13:1176448.